🚀 Biocon: Heading for All-Time High? 🚀
📉 CMP: ₹390
🔒 Stop Loss: ₹330
🎯 Targets: ₹428 | ₹478 | ₹560
🔍 Why Biocon Looks Promising?
✅ Weekly Rounding Bottom Breakout: Breakout triggered above ₹390
✅ Weekly Box Breakout: Confirmation above ₹398 strengthens the setup
✅ Final Confirmation: A weekly close above ₹402 will validate the breakout for a potential strong upside
💡 Strategy & Risk Management:
📈 Phased Entry: Build positions gradually post confirmation to manage risk effectively
🔒 Strict SL: Maintain stop loss at ₹330 to protect capital in case of reversal
📍 Outlook: Biocon is showing strong technical signals with an all-time high on the radar, making it a compelling positional trade setup.
📉 Disclaimer: Not SEBI-registered. Please do your own research or consult a financial advisor before investing.
#Biocon #PharmaStocks #TechnicalBreakout #AllTimeHigh #SwingTrading #StockMarket #InvestmentOpportunities
📉 CMP: ₹390
🔒 Stop Loss: ₹330
🎯 Targets: ₹428 | ₹478 | ₹560
🔍 Why Biocon Looks Promising?
✅ Weekly Rounding Bottom Breakout: Breakout triggered above ₹390
✅ Weekly Box Breakout: Confirmation above ₹398 strengthens the setup
✅ Final Confirmation: A weekly close above ₹402 will validate the breakout for a potential strong upside
💡 Strategy & Risk Management:
📈 Phased Entry: Build positions gradually post confirmation to manage risk effectively
🔒 Strict SL: Maintain stop loss at ₹330 to protect capital in case of reversal
📍 Outlook: Biocon is showing strong technical signals with an all-time high on the radar, making it a compelling positional trade setup.
📉 Disclaimer: Not SEBI-registered. Please do your own research or consult a financial advisor before investing.
#Biocon #PharmaStocks #TechnicalBreakout #AllTimeHigh #SwingTrading #StockMarket #InvestmentOpportunities
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.